Acta Veterinaria et Zootechnica Sinica ›› 2022, Vol. 53 ›› Issue (3): 834-846.doi: 10.11843/j.issn.0366-6964.2022.03.016

• PREVENTIVE VETERINARY MEDICINE • Previous Articles     Next Articles

Therapeutic Effect of Recombinant Adeno-Associated Virus Carrying CRISPR/Cas9 on Pseudorabies Virus-infected Mice

LI Zhaolong1,2*, ZHANG Huifang2, FENG Zhihua2, FANG Zhou2   

  1. 1. Institute of Animal Husbandry and Veterinary Medicine, Fujian Academy of Agricultural Sciences, Fuzhou 350013, China;
    2. Southern Biomedical Research Center, Fujian Normal University, Fuzhou 350015, China
  • Received:2021-07-14 Online:2022-03-23 Published:2022-03-31

Abstract: Pseudorabies virus (PRV) is the pathogen of pig pseudorabies. At present, there are more mature commercial vaccines in the clinical application, but the virus variation is frequent, so the occurrence of pseudorabies is still more common in pig breeding. How to clean the wild virus in the host is the key to the prevention and control of the disease. The adeno-associated virus (AAV) carrying CRISPR/Cas9 system toward TK, gE and VP16 genes of PRV were designed to weaken the virulence and replication ability of PRV, so as to achieve the purpose of eliminating PRV in mice model. The results showed that the pX601 recombinant plasmids (pXTK, pXGE, pXVP16) with CRISPR/Cas9 expression system and corresponding sgRNAs were successfully constructed, and these plasmids were further packaged into AAV-gE, AAV-VP16 and AAV-TK viruses with gene editing function, which significantly reduced the PRV load in cells and mice and increased the survival rate in the cell level and mouse infection test. The treatment result is positively correlated with the times of treatments. The results of the mouse model provide a new reference for the clinical treatment of porcine pseudorabies.

Key words: pseudorabies virus, CRISPR/Cas9 system, adeno-associated virus, therapy

CLC Number: